OS Therapies Incorporated
AMEX:OSTXBiotechnology
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
Volume 0.50M
Average 0.71M
OSTX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
OS Therapies IncorporatedAMEX: OSTX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $2.82M fell 23.7% year over year, behind the +166786.7% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at +2103.6% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +310482.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.82M-100.0% QoQ
- Last fiscal yearDec 2025
- $12.34B+310482.2% YoY
- LTMMar 2026
- $12.34B+166786.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 12.34B USD
- Year-over-year change
- +310482.2%
- 4-year CAGR
- +851.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.34B | +310482.2% |
| FY2024 | 2024-12-31 | 3.97M | +254.7% |
| FY2023 | 2023-12-31 | 1.12M | -2.9% |
| FY2022 | 2022-12-31 | 1.15M | -23.3% |
| FY2021 | 2021-12-31 | 1.5M | — |
Selling, General & Admin vs competitors
How OSTX compares with its peers on the latest reported figures
- OSTX's LTM Mar 2026 selling, general & admin of $12.34B is the highest of the 9 companies compared; the peer median is $15.75M.
- Its year-over-year change of +166786.7% is the 2nd highest of 8, against a peer median of +4.7%.
- Over three fiscal years its annual growth of +2103.6% compares with a peer median of -12.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $12.34B | +166786.7% | +2103.6% | — |
| LTM Mar 2026 | $8.41B | +205316.4% | +855.6% | — | |
| LTM Mar 2026 | $38.12M | -1.4% | +24.4% | 11443.7% | |
| LTM Jun 2026 | $19.35M | +4.7% | -9.7% | 92.1% | |
| LTM Mar 2026 | $17.75M | +26.9% | +12.0% | — | |
| LTM Mar 2026 | $13.76M | +12.8% | -21.8% | 600.0% | |
| LTM Mar 2026 | $10.46M | -6.1% | -14.5% | — | |
| LTM Mar 2026 | $8.86M | +3.4% | -29.6% | 626.3% | |
| LTM Jun 2024 | $7.81M | — | -15.8% | 957.8% | |
| Peer median (excluding OSTX) | $15.75M | +4.7% | -12.1% | 626.3% | |
Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.16M | 805 | 4.22K | 2.78K | 363.09K |
| Gross Profit | (1.16M) | (805) | (4.22K) | (2.78K) | (363.09K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.17M | 3.29M | 3.22M | 2.84M | 16.36B |
| Selling, General & Admin | 1.5M | 1.15M | 1.12M | 3.97M | 12.34B |
| Operating Expenses | 3.68M | 4.45M | 4.34M | 6.81M | 28.34M |
| Depreciation & Amortization | 805 | 805 | 4.22K | 2.78K | 363.09K |
| EBITDA | (4.84M) | (4.45M) | (4.34M) | (6.83M) | (28.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.84M) | (4.45M) | (4.34M) | (6.81M) | (28.71M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 249 |
| Interest Expense | 2.58M | 1.81M | 3.45M | 2.05M | 0 |
| Other Income / Expenses | (2.58M) | (1.81M) | (3.45M) | (2.07M) | (48.14K) |
| Income Before Tax | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.33) | (0.28) | (0.39) | (0.52) | (0.98) |
| EPS (Diluted) | (0.33) | (0.28) | (0.39) | (0.52) | (0.98) |
| Weighted Avg Shares | 23.1M | 23.1M | 20.05M | 20.87M | 29.25M |
| Weighted Avg Shares (Diluted) | 23.1M | 23.1M | 20.05M | 20.87M | 29.25M |
OS Therapies Incorporated
AMEX:OSTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.